Isotechnika to hold conference call to discuss positive PROMISE trial

    EDMONTON, June 3 /CNW/ - Isotechnika Inc. will hold a conference call to
discuss final Phase 2b PROMISE kidney transplant data for the Company's lead
immunosuppressive drug, voclosporin, on Wednesday, June 4th at
9:00 a.m. ET/7:00 a.m. MT.
    As previously announced, the final Phase 2b kidney transplant trial
(PROMISE) results will be presented during an oral presentation by Dr. Osama
Gaber, Director of Transplantation, Vice-Chair for Administration and Faculty
Affairs, Department of Surgery, The Methodist Hospital, Cornell University in
New York at the 2008 American Transplant Congress in Toronto, Ontario.
Dr. Gaber, as one of the principal investigators in the PROMISE trial, will
present detailed data including the primary endpoint as determined by biopsy
proven acute rejection and relevant safety data. Dr. Gaber's presentation is
scheduled to take place on Tuesday, June 3 at 4:50 p.m. ET.
    All interested parties will be able to access the live event (listen only
mode) through the Company's corporate web site at and
access the replay at 416-640-1917 or 877-289-8525 using the pass code,

    About Isotechnika Inc.
    Edmonton-based Isotechnika Inc. is an international biopharmaceutical
company focused on the discovery and development of novel immunosuppressive
therapeutics that are designed to offer advantages over other currently
available treatments. There is a significant unmet medical need in the
treatment of both solid organ transplantation and autoimmune disease. It is
estimated that the market potential will exceed $4 billion annually in sales
for calcineurin inhibitors such as voclosporin by 2010.
    Voclosporin is a next generation calcineurin inhibitor, which recently
completed a Phase 2b North American trial for the prevention of kidney
rejection following transplantation. An extension to the Phase 2b trial and a
combined Phase 3 European/Canadian trial for the treatment of moderate to
severe psoriasis are ongoing. Our partner, Lux Biosciences, is currently
conducting three separate Phase 2/3 pivotal trials investigating voclosporin
(referred to as LX211 by Lux) for the treatment of uveitis. Voclosporin has
been approved to enter First-in-Man trials as the drug utilized in the
CINATRA(TM) Drug Coated Coronary Stent system developed by the Company's
partner, Atrium Medical Corporation.
    Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol "ISA". More information on Isotechnika can be found

    Forward-Looking Statements
    This press release may contain forward-looking statements. Such
forward-looking statements involve known and unknown risks, uncertainties and
other factors that may cause actual results, events or developments to be
materially different from any future results, events or developments expressed
or implied by such forward-looking statements. Forward-looking statements,
including the Company's belief as to the potential of its products, the
Company's expectations regarding the issuance of additional patents and the
Company's ability to protect its intellectual property, involve known and
unknown risks and uncertainties, which could cause the Company's actual
results to differ materially from those in the forward-looking statements.
Such risks and uncertainties include, among others, securing and maintaining
corporate alliances, the need for additional capital and the effect of capital
market conditions and other factors on capital availability, the ability to
economically manufacture its products, the potential of its products, the
success and timely completion of clinical studies and trials, the Company's
ability to successfully commercialize its products, competition, the ability
of the Company to defend its patents from infringement by third parties, and
the risk that the Company's patents may be subsequently shown to be invalid or
infringe the patents of others. Additional risks and uncertainties relating to
the Company and its business can be found in the "Risk Factors" section of the
Company's Annual Information Form. These factors should be considered
carefully and readers are cautioned not to place undue reliance on such
forward-looking statements.

    %SEDAR: 00010508E

For further information:

For further information: Stephanie Gillis-Paulgaard, Director, Corporate
Communications, Isotechnika Inc., Phone: (780) 909-4661, Fax: (780) 484-4105,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890